TY - JOUR
T1 - Behcet's disease in patients with chronic myelogenous leukemia
T2 - Possible role of interferon-alpha treatment in the occurrence of Behcet's symptoms
AU - Budak-Alpdoǧan, T.
AU - Demirçay, Z.
AU - Alpdogan, O.
AU - Direskeneli, H.
AU - Ergun, T.
AU - Bayik, M.
AU - Akoglu, T.
PY - 1997
Y1 - 1997
N2 - Two patients with chronic myelogenous leukemia (CML) who developed characteristic features of Behcet's disease (BD) during alpha-interferon (IFN-α) treatment and another patient who had a diagnosis of BD preceding CML are presented. In the first two patients, features of BD appeared 6 months after the initiation of IFN-α treatment; they included recurrent oral aphthae, genital ulceration, arthritis, folliculitis, and a positive skin pathergy test. The third patient, however, had a diagnosis of Behcet's disease 4 years before diagnosis of Philadelphia-positive CML. We prospectively examined the skin pathergy reaction in a group of patients with CML, multiple myeloma, and hairy cell leukemia both before and after IFN-α treatment and found two additional patients with CML who developed a positive skin pathergy test following IFN-α treatment.
AB - Two patients with chronic myelogenous leukemia (CML) who developed characteristic features of Behcet's disease (BD) during alpha-interferon (IFN-α) treatment and another patient who had a diagnosis of BD preceding CML are presented. In the first two patients, features of BD appeared 6 months after the initiation of IFN-α treatment; they included recurrent oral aphthae, genital ulceration, arthritis, folliculitis, and a positive skin pathergy test. The third patient, however, had a diagnosis of Behcet's disease 4 years before diagnosis of Philadelphia-positive CML. We prospectively examined the skin pathergy reaction in a group of patients with CML, multiple myeloma, and hairy cell leukemia both before and after IFN-α treatment and found two additional patients with CML who developed a positive skin pathergy test following IFN-α treatment.
UR - https://www.scopus.com/pages/publications/0030614596
UR - https://www.scopus.com/inward/citedby.url?scp=0030614596&partnerID=8YFLogxK
U2 - 10.1007/s002770050255
DO - 10.1007/s002770050255
M3 - Article
C2 - 9031616
AN - SCOPUS:0030614596
SN - 0939-5555
VL - 74
SP - 45
EP - 48
JO - Annals of Hematology
JF - Annals of Hematology
IS - 1
ER -